Track Immunicum AB (publ) — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immunicum AB (publ) IMMU.ST Open Immunicum AB (publ) in new tab

5.64 SEK
EPS
-1.90
P/B
0.62
ROE
-18.41
Beta
0.71
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 20, 2026
EPS-1.90
Book Value9.54
Price to Book0.62
Debt/Equity3.22
% Insiders67.210%
Growth
Revenue Growth-0.52%
Estimates
Forward P/E-12.02
Forward EPS-0.49

DCF Valuation

Tweak assumptions to recompute fair value for Immunicum AB (publ) (IMMU.ST)
Currency: SEK
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Immunicum AB (publ) Logo Immunicum AB (publ) Analysis (IMMU.ST)

Sweden Health Care Official Website Stock

Is Immunicum AB (publ) a good investment? Immunicum AB (publ) (IMMU.ST) is currently trading at 5.64 SEK.

Earnings Schedule: Immunicum AB (publ) is expected to release its next earnings report on Aug. 20, 2026. The market consensus estimate for Forward EPS is -0.49.

Investor FAQ

Does Immunicum AB (publ) pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immunicum AB (publ)?

Immunicum AB (publ) is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 20, 2026. The company currently has a trailing EPS of -1.90.

Company Profile

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Exchange Ticker
STO (Sweden) IMMU.ST

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 3, 2024 0.050000
July 10, 2023 1.080000
Dec. 5, 2017 1.070000
May 24, 2016 1.040000
April 9, 2014 1.060000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion